deltatrials
Completed PHASE2/PHASE3 INTERVENTIONAL 3-arm NCT02069899

A Study for Long-term Follow-up of Hemophagocytic Lymphohistiocytosis (HLH) Participants Who Received Treatment With Emapalumab (NI-0501), an Anti-interferon Gamma Monoclonal Antibody

A Multicenter Study for the Long-term Follow-up of HLH Patients Who Received Treatment With NI-0501, an Anti-interferon Gamma Monoclonal Antibody

Sponsor: Seventh Framework Programme

Interventions Emapalumab
Updated 20 times since 2017 Last updated: Jun 1, 2022 Started: Aug 4, 2014 Primary completion: May 18, 2021 Completion: May 18, 2021
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2/PHASE3 clinical study on Hemophagocytic Lymphohistiocytosis, this trial is completed. The trial is conducted by Seventh Framework Programme and has accumulated 20 data snapshots since 2014. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jul 2017 · 5 months · monthly snapshot~Jul 2017 – ~Apr 2018 · 9 months · monthly snapshot~Apr 2018 – ~Jun 2018 · 2 months · monthly snapshot~Jun 2018 – ~Mar 2019 · 9 months · monthly snapshot~Mar 2019 – ~Jun 2019 · 3 months · monthly snapshot~Jun 2019 – ~Jul 2019 · 30 days · monthly snapshot~Jul 2019 – ~Sep 2019 · 2 months · monthly snapshot~Sep 2019 – ~Oct 2019 · 30 days · monthly snapshot~Oct 2019 – ~Nov 2019 · 31 days · monthly snapshot~Nov 2019 – ~Jul 2020 · 8 months · monthly snapshot~Jul 2020 – ~Nov 2020 · 4 months · monthly snapshot~Nov 2020 – ~Jan 2021 · 2 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Sep 2021 · 7 months · monthly snapshot~Sep 2021 – ~Jul 2022 · 10 months · monthly snapshot~Jul 2022 – ~Jul 2024 · 24 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 8 months · monthly snapshot

Change History

20 versions recorded
  1. Sep 2025 — Present [monthly]

    Completed PHASE2/PHASE3

  2. Sep 2024 — Sep 2025 [monthly]

    Completed PHASE2/PHASE3

  3. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2/PHASE3

    Phase: PHASE2_PHASE3PHASE2/PHASE3

  4. Jul 2022 — Jul 2024 [monthly]

    Completed PHASE2_PHASE3

    Phase: NAPHASE2_PHASE3

  5. Sep 2021 — Jul 2022 [monthly]

    Completed NA

    Status: Active Not RecruitingCompleted

Show 15 earlier versions
  1. Feb 2021 — Sep 2021 [monthly]

    Active Not Recruiting NA

  2. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting NA

  3. Nov 2020 — Jan 2021 [monthly]

    Active Not Recruiting NA

    Status: RecruitingActive Not Recruiting

  4. Jul 2020 — Nov 2020 [monthly]

    Recruiting NA

  5. Nov 2019 — Jul 2020 [monthly]

    Recruiting NA

  6. Oct 2019 — Nov 2019 [monthly]

    Recruiting NA

  7. Sep 2019 — Oct 2019 [monthly]

    Recruiting NA

  8. Jul 2019 — Sep 2019 [monthly]

    Recruiting NA

  9. Jun 2019 — Jul 2019 [monthly]

    Recruiting NA

  10. Mar 2019 — Jun 2019 [monthly]

    Recruiting NA

  11. Jun 2018 — Mar 2019 [monthly]

    Recruiting NA

  12. Apr 2018 — Jun 2018 [monthly]

    Recruiting NA

  13. Jul 2017 — Apr 2018 [monthly]

    Recruiting NA

  14. Feb 2017 — Jul 2017 [monthly]

    Recruiting NA

  15. Jan 2017 — Feb 2017 [monthly]

    Recruiting NA

    First recorded

Aug 2014

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Seventh Framework Programme
  • Swedish Orphan Biovitrum
Data source: Swedish Orphan Biovitrum

For direct contact, visit the study record on ClinicalTrials.gov .